Compare KB Financial Group, Inc. (KB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? KB Financial Group, Inc. trades at $123.11 (market cap $42.62B), while Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B). The key difference: KB Financial Group, Inc. is far larger — about 19.9× Recursion Pharmaceuticals Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KB | RXRX | |
|---|---|---|
Market Cap | $42.62B | $2.14B |
Volume | 164,291 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $132.88 | $6.79 |
52-Week Low | $77.50 | $2.84 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $215.53T | $1.66B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group trades at $122.78, down 1.56% today, with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with consistent earnings beats, growing revenue from $21.23T to $22.37T projected for 2026, and improving profit margins reaching 28.09%. Recent analyst coverage shows 33% buy ratings with positive momentum commentary from multiple financial outlets.
The outlook remains positive given KB's attractive valuation at 9.68 P/E and 0.94 P/B, coupled with sustained earnings growth. Key risks include market volatility and the company's significant investment outflows. Analyst consensus leans neutral with 67% hold ratings, suggesting cautious optimism for this value-oriented financial stock.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
